BCC Research Publishes a New Report on Global Markets for Insulin Drug and Delivery Devices
The global market for insulin drug and delivery devices was valued at $24 billion in 2012 and is expected to reach $25.7 billion by 2013. BCC Research projects the market to reach nearly $40.2 billion by 2018 and register a compound annual growth rate (CAGR) of 9.3%.
Wellesley, MA (PRWEB) September 18, 2013
According to a new technical market research report, Global Markets for Emerging Insulin Drug and Delivery Technologies from BCC Research (http://www.bccresearch.com), the global market for insulin drug and delivery devices was valued at $24 billion in 2012 and is expected to reach $25.7 billion by 2013. BCC Research projects the market to reach nearly $40.2 billion by 2018 and register a compound annual growth rate (CAGR) of 9.3%.
Diabetes is one of the leading causes of death as well as a major cause for comorbidities such as stroke and cerebrovascular events in United States. According to the 2011 National Diabetes Factsheet, nearly 8.3% of the U.S. population has diabetes, with total estimated cost ranging up to $245 billion for diagnosed diabetes. The increasing demand for expedient insulin delivery devices such as pens and pumps may help diabetes patients optimize blood glucose control and minimize the risk for associated health issues that might arise from the disease. Rising cases of diabetes in the U.S. globally justify the need for ongoing research and vindicate the debates over the developments taking place in this field.
The global market for emerging insulin drug and delivery technologies is very dynamic and is developing at a fast pace. The industry has progressed steadily during the past decade and will continue to sustain growth in the coming four to five years. Modern industries and research institutes have begun to explore newer method for diabetes control in adults and juveniles, leading to a steady market for these technologies. New advancements, new product launches, along with increased awareness and early detection of the disease, are expected to influence the market growth in the foreseeable future.
This comprehensive report explores present and future strategies within the insulin drug and delivery market which includes syringes, pumps, pens, and many new methods of delivery. It also presents, the classifications, comparisons, and usage of different insulin types and devices. The report discusses the strength and weaknesses of each technology type in the light of new technologies, growing competition, and changing customer needs.
This new report presents a detailed analysis of insulin drugs and delivery industry structure, breaking down revenues by type as well as by region, including India, China, Japan, Korea, Taiwan, Canada, Africa, Australia, and New Zealand. The scope of this study encompasses insulin drugs and delivery in pharmaceutical and biotechnology markets with its classification and its usage in diabetes types. BCC Research has analyzed each market and its applications, as well as its regulatory environment, technology and market share in this report. The markets, such as type 1 diabetes, type 2 diabetes, and gestational diabetes, are analyzed for the years 2011 and 2012. The markets are projected through the end of 2013 and for a five-year period until 2018. The applications for insulin drugs and delivery are also discussed in a separate section with emphasis on their usage in treating different types of diabetes. The report also covers significant patents and their allotments in each category. In addition, the study reviews the acquisition strategies and collaborations of the key players.
This study contributes to the areas of market growth for insulin drug and delivery manufacturers and users. It is a valuable resource for pharmaceutical biotechnical companies, research institutes, hospitals, and physicians.
For the original version on PRWeb visit: http://www.prweb.com/releases/2013/9/prweb11126499.htm